drugset

drugset / Trial / NCT00371059

Memantine for Agitation in Dementia

NCT00371059 ↗

Phase 4 Completed 153 enrolled East Kent Hospitals University NHS Foundation Trust Indiana University · collab Institute of Psychiatry, London · collab University College, London · collab University of London · collab University of Oxford · collab

RandomizedSingle-groupQuadruple-blindTreatment

Summary

We plan to evaluate the use of memantine in Alzheimer's disease to control agitation in the acute situation i.e under 12 weeks

Timeline

Start: 2007-09
Primary completion: 2009-06
Completion: 2009-09

Outcome

Missed primary endpoint

paper no significant differences in the primary outcome, 6 weeks CMAI, between memantine and placebo PMID 22567095 ↗

Publications

Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, Ballard C, Boustani M, Katona C, Livingston G. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS One. 2012;7(5):e35185. doi: 10.1371/journal.pone.0035185. Epub 2012 May 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Memantine	Unknown	10 mg	—

Indications